



## Chediak-Higashi Syndrome

Camilo Toro, MD,<sup>1</sup> Marie Morimoto, PhD,<sup>2</sup> May Christine Malicdan, MD, PhD,<sup>3</sup> David R Adams, MD, PhD,<sup>4</sup> and Wendy J Inrone, MD<sup>1</sup>

Created: March 3, 2009; Updated: December 21, 2023.

### Summary

#### Clinical characteristics

Chediak-Higashi syndrome (CHS) is characterized by partial oculocutaneous albinism (OCA), immunodeficiency, a mild bleeding tendency, and late adolescent- to adult-onset neurologic manifestations (e.g., learning difficulties, peripheral neuropathy, ataxia, and parkinsonism). While present in nearly all individuals with CHS, these clinical findings vary in severity.

Of note, all individuals with CHS are at risk of developing neurologic manifestations and hemophagocytic lymphohistiocytosis (HLH).

Individuals with severe childhood-onset presentations are considered to have "classic" CHS, whereas individuals with milder adolescent- to adult-onset presentations are considered to have "atypical" CHS. Because of the considerable overlap between classic CHS and atypical CHS, the disorder is best understood as a continuum of severe to milder phenotypes, with the universal feature being the pathognomonic giant granules within leukocytes observed on peripheral blood smear.

#### Diagnosis/testing

The clinical diagnosis of CHS is established in a proband with suggestive clinical findings by identification of the pathognomonic giant granules within leukocytes on peripheral blood smear and/or biallelic pathogenic variants in *LYST* on molecular genetic testing.

**Author Affiliations:** 1 Staff Clinician, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; Email: toroc@mail.nih.gov; Email: wintrone@mail.nih.gov. 2 Scientist I (contractor), National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; Email: marie.morimoto@nih.gov. 3 Staff Scientist, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; Email: malicdanm@mail.nih.gov. 4 Senior Clinician, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; Email: david.adams@nih.gov.

## Management

*Targeted therapy:* The only targeted therapy currently available is hematopoietic stem cell transplantation (HSCT). HSCT can correct the hematologic and immunologic manifestations of CHS but does not appear to protect against the development of neurologic manifestations.

*Supportive care:* Multidisciplinary care is recommended, including specialists in ophthalmology and low vision services, infectious disease for management and prevention, hematology (to manage the bleeding disorder, HSCT, and treatment of HLH), neurology and psychiatry, physical therapy, occupational therapy, and (for children) neuropsychology or developmental pediatrics to address educational and emotional needs or (for adults) neuropsychology.

*Surveillance:* To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, routinely scheduled follow-up evaluations by the multidisciplinary specialists are recommended.

*Agents/circumstances to avoid:* Live vaccines given the risk of infection due to immunodeficiency; all nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) given the risk of exacerbating the bleeding tendency.

*Evaluation of relatives at risk:* It is appropriate to evaluate the older and younger sibs of a proband as early as possible. Early diagnosis may provide the opportunity to perform HSCT prior to the development of HLH.

*Pregnancy management:* Although data are limited, to date females with CHS report uneventful pregnancy, labor, and delivery. However, because of concerns about bleeding during delivery and the postpartum period, developing a plan prior to delivery to address this issue is recommended.

## Genetic counseling

CHS is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a *LYST* pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the *LYST* pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.

## GeneReview Scope

Chediak-Higashi syndrome (CHS) is characterized by partial oculocutaneous albinism (OCA), immunodeficiency, a mild bleeding tendency, and late adolescent- to adult-onset neurologic manifestations (e.g., learning difficulties, peripheral neuropathy, ataxia, and parkinsonism). All individuals are at risk of developing hemophagocytic lymphohistiocytosis (HLH).

While present in nearly all individuals with CHS, these clinical findings vary in severity. Individuals with severe presentations (see *GeneReview Scope*) are considered to have "classic" CHS, whereas individuals with milder presentations are considered to have "atypical" CHS. Because of the considerable overlap between classic CHS and atypical CHS, the disorder is best understood as a continuum of severe to milder phenotypes, with the universal feature being the pathognomonic giant granules within leukocytes observed on peripheral blood smear.

**GeneReview Scope: Chediak-Higashi Syndrome Clinical Continuum**

Severity	Age at Diagnosis	OCA	HLH <sup>1</sup> Risk	Immune Deficiency	Bleeding Diathesis	Neurologic Involvement
<b>Severe: Classic CHS</b>	Earlier in life (childhood)	Mild to moderate	Higher	Frequent, severe, & unusual infections	Similar across phenotypic continuum	
<b>Milder: Atypical CHS</b>	Later in life (adolescent- or adult-onset)	Absent to mild	Lower	May be only mild or no unusual infections		

Based on Introne et al [2017], Kuptanon et al [2023]

CHS = Chediak-Higashi syndrome; HLH = hemophagocytic lymphohistiocytosis; OCA = oculocutaneous albinism

1. Also called "accelerated phase"

## Diagnosis

### Suggestive Findings

The diagnosis of Chediak-Higashi syndrome (CHS) **should be suspected** in a proband with any of the following clinical features, supportive laboratory findings, and family history.

#### Clinical features

- **Oculocutaneous albinism (OCA)** with residual pigmentation characterized by:
  - Signs and symptoms of low vision typical of OCA
  - Reduced iris pigmentation (manifesting as iris transillumination often only on ophthalmologic examination). Note that irides may be darker than the light blue that is often associated with OCA.
  - Reduced retinal pigmentation
  - Hair that may have a silvery-gray sheen
- A significant history of infections (particularly bacterial) of the skin and respiratory tract; also increased susceptibility to periodontal disease
- Mild bleeding tendency associated with platelet dysfunction such as epistaxis, gum/mucosal bleeding, and easy bruising
- Increased risk for hemophagocytic lymphohistiocytosis (HLH) (previously called "CHS accelerated phase"). Clinical findings and diagnostic criteria are the same as those for [familial hemophagocytic lymphohistiocytosis](#).
- Childhood- to early adult-onset neurologic manifestations, including:
  - Learning difficulties
  - Peripheral neuropathy
  - Ataxia
  - Parkinsonism

#### Supportive laboratory findings

- White blood cell (WBC) giant granules (also called "inclusions"), peroxidase-positive granules primarily in polymorphonuclear neutrophils (PMNs) and to a lesser extent in lymphocytes (Figure 1c-1e), are the most reliable diagnostic criterion for CHS. Nonetheless, giant granules may be overlooked in a routinely evaluated complete blood count (CBC) unless a peripheral smear is reviewed.
  - Although the giant granules are seen using routine staining techniques, in some individuals with atypical CHS the presence of these giant granules can be less striking and thus missed by routine evaluation.

- Slide review is optimally conducted by a hematologist or other specialist with experience reviewing blood smears for the presence of abnormal granules.
- Because the finding of WBC giant granules is the most reliable clinical diagnostic criterion for CHS, the combination of any of the other hematologic findings listed below should prompt review of a peripheral blood smear to evaluate for giant granules.
- Other hematologic findings:
  - Absent or reduced number and/or irregular morphology of platelet-dense bodies (required for the secondary wave of platelet aggregation) on whole-mount electron microscopy (Figure 1a, 1b)
  - Normal or reduced number of natural killer cells with abnormal (reduced) function
  - Neutropenia
  - Normal immunoglobulins, complement, antibody production, and delayed hypersensitivity

**Other.** Pigment clumping on polarized light microscopy hair analysis (Figure 1f, 1g)

**Family history** is consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis. Note: When evaluating sibs of a proband for the purpose of the family history, clinicians should have a high level of suspicion for all findings that may be associated with CHS, since presenting manifestations may vary in sibs with the same biallelic *LYST* pathogenic variants.

## Establishing the Diagnosis

The **clinical diagnosis** of CHS is **established** in a proband by identification of the pathognomonic giant granules within leukocytes on peripheral blood smear (see Suggestive Findings). The **molecular diagnosis** of CHS is **established** in a proband by the identification of biallelic pathogenic (or likely pathogenic) variants in *LYST* on molecular genetic testing [Sharma et al 2020, Morimoto et al 2023] (see Table 1).


Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variant" and "likely pathogenic variant" are synonymous in a clinical setting, meaning that both are considered diagnostic and can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variant" in this *GeneReview* is understood to include likely pathogenic variants. (2) Identification of biallelic *LYST* variants of uncertain significance (or of one known *LYST* pathogenic variant and one *LYST* variant of uncertain significance) does not establish or rule out the diagnosis.

Molecular genetic testing approaches can include a combination of **gene-targeted testing** (single-gene testing, multigene panel) and **comprehensive genomic testing** (exome sequencing, genome sequencing). Gene-targeted testing requires that the clinician determine which gene(s) are likely involved (Option 1), whereas comprehensive genomic testing does not (Option 2).

### Option 1

**Single-gene testing is an option when laboratory and clinical findings are strongly suggestive of the diagnosis.** Sequence analysis of *LYST* is performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. Note: Depending on the sequencing method used, single-exon, multiexon, or whole-gene deletions/duplications may not be detected. If only one or no variant is detected by the sequencing method used, the next step is to perform gene-targeted deletion/duplication analysis to detect exon and whole-gene deletions or duplications.

**An albinism or neutropenia panel** that includes *LYST* and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are



**Figure 1.** Examples of granules in polymorphonuclear neutrophils, platelet-dense bodies, and pigment in hair shafts for controls, classic Chediak-Higashi syndrome (CHS), and atypical CHS

- Whole-mount electron microscopy (EM) of control platelets shows several dense bodies per platelet (arrows).
- Some CHS platelets have no dense bodies (asterisk) and others have irregular electron-dense granules (arrows).
- Normal control polymorphonuclear neutrophils (PMNs) contain numerous small cytoplasmic granules.
- The blood smear derived from an individual with classic severe CHS shows PMNs that contain enlarged intracytoplasmic granules.
- PMNs from an adult-onset, mildly affected individual with atypical CHS contain many granules that are larger than normal but smaller than those of the individual with classic CHS seen in 1d.
- Control hair shows pigment that is evenly distributed throughout the shaft.
- Hair of an individual with classic CHS shows an irregular distribution of large and small pigment clumps.

likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.



For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#).

## Option 2

**Comprehensive genomic testing** does not require the clinician to determine which gene is likely involved. **Exome sequencing** is most commonly used; **genome sequencing** is also possible. To date, the majority of *LYST* pathogenic variants reported (e.g., missense, nonsense) are within the coding region or close to canonical splices and are therefore likely to be identified by exome sequencing.

For an introduction to comprehensive genomic testing click [here](#). More detailed information for clinicians ordering genomic testing can be found [here](#).

**Table 1.** Molecular Genetic Testing Used in Chediak-Higashi Syndrome

Gene <sup>1</sup>	Method	Proportion of Pathogenic Variants <sup>2</sup> Detectable by Method
<i>LYST</i>	Sequence analysis <sup>3</sup>	~97% <sup>4</sup>
	Gene-targeted deletion/duplication analysis <sup>5</sup>	~2% <sup>6</sup>
	Unknown	~1% <sup>7</sup>

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include missense, nonsense, and splice site variants and small intragenic deletions/insertions; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. Morimoto et al [2023] and data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2020]

5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications. Exome and genome sequencing may be able to detect deletions/duplications using breakpoint detection or read depth; however, sensitivity can be lower than gene-targeted deletion/duplication analysis.

6. Certain et al [2000], Fusaro et al [2021], Kuptanon et al [2023]

7. Several pathogenic variants were identified that were determined to lead to exon skipping by cDNA Sanger sequencing, but the exact genomic variant leading to these exon-skipping events has not been determined [Kuptanon et al 2023].

## Clinical Characteristics

### Clinical Description

Chediak-Higashi syndrome (CHS) is characterized by partial oculocutaneous albinism (OCA), immunodeficiency, and a mild bleeding tendency. These features are present in nearly all individuals with CHS but to a very variable degree. Affected individuals with severe presentations (i.e., OCA; early-onset, recurrent, severe infections; and a bleeding diathesis) are considered to have "classic" CHS. Individuals with milder phenotypes (e.g., later-onset, milder pigmentary, immunologic, and hematologic features) are considered to have "atypical" CHS (also referred to as "mild" or "adolescent" CHS). Both groups of individuals are at risk of developing hemophagocytic lymphohistiocytosis (HLH), previously called "the accelerated phase," with the highest risk of HLH (~85%) in individuals with classic CHS.

Over time, it has become apparent that the classification of CHS into "classic" vs "atypical" phenotypes is arbitrary, as the considerable overlap of the two groups means that this disorder is best understood as a

continuum of severe to milder phenotypes, with the universal feature being the pathognomonic giant granules within leukocytes observed on peripheral blood smear.

Although the proportion of individuals with atypical CHS is unknown [Karim et al 2002, Westbroek et al 2007], it is likely underrecognized. In some individuals with atypical CHS, the neurologic findings may be the predominant manifestation. Additionally, some individuals may not be diagnosed until the third decade of life or later [Weisfeld-Adams et al 2013, Yarnell et al 2020].

**Table 2.** Chediak-Higashi Syndrome: Phenotypic Continuum

Feature	Degree of Involvement <sup>1</sup>
Oculocutaneous albinism	Ranges from mild/moderate in classic CHS to mild/absent in atypical CHS
Immunodeficiency / increased risk of infection	Ranges from infantile onset of frequent and often severe infections in classic CHS to absence of a noticeable increase in severity or frequency of infections in atypical CHS
Bleeding tendency	Similar bleeding diathesis in all individuals with CHS
Neurologic involvement	Wide-ranging and nonspecific features in all individuals with CHS.
Hemophagocytic lymphohistiocytosis <sup>2</sup>	Occurs in the majority of individuals with CHS who have not undergone hematopoietic stem cell transplantation.

Based on Introne et al [2017], Kuptanon et al [2023]

1. The same CHS-related features are present in nearly all individuals with classic and atypical CHS but to a very variable degree.

2. Also called "accelerated phase"

**Partial oculocutaneous albinism (OCA).** Pigment dilution, which can involve eyes, hair, and skin, is highly variable.

Reduced iris pigmentation and iris transillumination may be subtle. Affected individuals may have decreased retinal pigmentation and nystagmus. Visual acuity varies from normal to moderately reduced.

The hair has a "silvery" or metallic appearance. Pigment clumping within the shaft of the hair is generally observed by light microscopy (Figure 1g) [Smith et al 2005].

Skin pigment dilution may not be appreciated unless compared to the pigmentation of family members. Individuals with darker skin tone may observe areas with scattered hyper- and hypopigmentation.

Although partial OCA was once thought to be a diagnostic criterion for CHS, at least two individuals with atypical CHS had no evidence of OCA [Introne et al 2017].

**Immunodeficiency.** Frequent infections usually begin in infancy and are often severe in classic CHS. Individuals with atypical CHS may not have a noticeable increase in severity or frequency of infections.

Bacterial infections are most common, with *Staphylococcus* and *Streptococcus* species predominating; viral and fungal infections can also occur [Introne et al 1999]. Infections of the skin and upper respiratory tract are the most common.

Periodontitis, an important manifestation of immunologic dysfunction [Thumbigere Math et al 2018, de Arruda et al 2023], can be the clinical finding that leads to the correct diagnosis [Bailleul-Forestier et al 2008].

Neutropenia may be present and, in some individuals, cycles between normal absolute neutrophil counts and neutropenia (also called "cyclic neutropenia").

**Bleeding tendency.** The bleeding diathesis in CHS, a result of absent or severely reduced platelet-dense granules, is present in both classic and atypical CHS. Clinical manifestations are generally mild and include epistaxis, gum/mucosal bleeding, and easy bruising. The bleeding diathesis may also be subtle (i.e., generally not requiring

medical intervention) and thus may not be identified as a health concern by affected persons. However, with trauma or invasive procedures, bleeding may be more severe and prolonged.

**Neurologic involvement.** Despite successful hematologic and immunologic outcomes with allogeneic hematopoietic stem cell transplantation (HSCT) to treat hematologic findings, neurologic involvement nonetheless manifests by early adulthood.

Neurologic features are similar across the CHS phenotypic spectrum; thus, individuals with classic and atypical CHS cannot be distinguished neurologically [Introne et al 2017]. Due to the wide range of neurologic features that can occur, findings among affected individuals are variable and nonspecific. Likewise, age of onset and disease progression also vary. While learning difficulties may be present in childhood and can be considered developmental in nature, other neurologic signs and symptoms are generally not observed until late adolescence or early adulthood and are progressive. Neurologic findings can include:

- Learning difficulties in childhood [Introne et al 2017, Shirazi et al 2019]
- Sensory neuropathy. Onset in late adolescence or early third decade and slowly progresses to sensorimotor neuropathies and/or diffuse motor neuronopathy [Lehky et al 2017]
- Cerebellar dysfunction. Onset in late adolescence or early adulthood [Introne et al 2017]
- Optic neuropathy. Onset in late adolescence or early adulthood [Desai et al 2016]
- Spastic paraplegia. Onset in early to middle adulthood [Shimazaki et al 2014, Koh et al 2022]
- Tremor, which can include kinetic and postural tremor
- Parkinsonism, including L-dopa-responsive parkinsonism, may occur as early as the second or third decade [Bhambhani et al 2013, Weisfeld-Adams et al 2013]
- Progressive cognitive decline late in the disease course

**Hemophagocytic lymphohistiocytosis (HLH; also known as the "accelerated phase")** occurs in the majority of individuals with CHS who have not undergone HSCT [Lozano et al 2014] and can occur at any age. Although individuals with atypical CHS are thought to be at lower risk of HLH than individuals with classic CHS, the frequency of occurrence in atypical CHS is unknown.

Originally thought to be a malignancy resembling lymphoma, the "accelerated phase" is now known to be HLH characterized by multiorgan inflammation. Manifestations include fever, lymphadenopathy, hepatosplenomegaly, anemia, neutropenia, and thrombocytopenia.

Triggers of HLH remain unclear. Although infection with Epstein-Barr virus is thought to hasten development of HLH, this relationship has never been proven. Abnormal function of NK cells and cytolytic T cells is also believed to contribute to development of HLH [Jessen et al 2011, Gil-Krzewska et al 2016].

**Prognosis.** HLH and its complications are the most common cause of mortality in individuals with CHS [Lozano et al 2014].

## Genotype-Phenotype Correlations

Clinical phenotypes of CHS have been correlated with classes of *LYST* pathogenic variants [Karim et al 2002, Zarzour et al 2005, Westbroek et al 2007, Morimoto et al 2023].

- Loss-of-function *LYST* pathogenic variants (e.g., nonsense, frameshift, canonical splice site, single- or multiexon deletions) are typically associated with classic CHS.
- Missense pathogenic variants and in-frame deletions of *LYST* are associated with atypical CHS; however, individuals with biallelic missense pathogenic variants with classic CHS and HLH have been reported [Sánchez-Guiu et al 2014].



## Prevalence

Fewer than 500 individuals with CHS have been reported [Morimoto et al 2023, Talbert et al 2023].

Exact prevalence is difficult to determine, as some individuals have been reported in the literature more than once. In addition, the broad phenotypic spectrum that has become evident since the early descriptions of CHS suggests that many mildly affected individuals may be underrecognized or underreported.

## Genetically Related (Allelic) Disorders

No phenotypes other than those discussed in this *GeneReview* are known to be associated with germline pathogenic variants in *LYST*.

## Differential Diagnosis

The diagnosis of Chediak-Higashi syndrome (CHS) should be considered in individuals with pigment dilution defects of the hair, skin, or eyes; congenital or transient neutropenia; immunodeficiency; and otherwise unexplained neurologic abnormalities or neurodegeneration. Each of these findings may be variably represented or absent in affected individuals; therefore, heightened suspicion is needed to pursue an accurate diagnosis.

**Table 3.** Genes of Interest in the Differential Diagnosis of Chediak-Higashi Syndrome

Gene(s)	Disorder	MOI	Clinical Features	Comment
<i>AP3B1</i> <i>AP3D1</i> <i>BLOC1S3</i> <i>BLOC1S5</i> <i>BLOC1S6</i> <i>DTNBP1</i> <i>HPS1</i> <i>HPS3</i> <i>HPS4</i> <i>HPS5</i> <i>HPS6</i>	Hermansky-Pudlak syndrome (HPS)	AR	<ul style="list-style-type: none"> <li>OCA &amp; a bleeding diathesis secondary to absent platelet-dense bodies</li> <li>Of the HPS subtypes, <i>AP3B1</i>-related HPS (HPS2) most closely resembles CHS. In addition to the albinism &amp; bleeding diathesis, persons w/HPS2 have congenital neutropenia, a recurrent pattern of severe bacterial infections, &amp; pulmonary fibrosis &amp; are at risk for HLH, although the risk is less than for CHS.</li> </ul>	The distinction between CHS & HPS2 depends on identifying giant intracellular granules w/in the neutrophils of those persons w/CHS &/or molecular genetic testing.
<i>DCT</i> <i>LRMDA</i> <i>OCA2</i> <i>SLC24A5</i> <i>SLC45A2</i> <i>TYR</i> <i>TYRP1</i>	Nonsyndromic oculocutaneous albinism (OCA)	AR	<ul style="list-style-type: none"> <li>Cutaneous &amp; ocular hypopigmentation</li> <li>Impaired melanin biosynthesis leads to hypopigmentation in the skin, hair, &amp; eyes w/characteristic ocular abnormalities.</li> </ul>	<ul style="list-style-type: none"> <li>Neither an infectious history resulting from neutropenia nor neurologic abnormalities accompany the nonsyndromic OCA types.</li> <li>OCA is common enough (~1:18,000) that it may coexist w/other conditions, incl primary immunodeficiencies.</li> </ul>

Table 3. continued from previous page.

Gene(s)	Disorder	MOI	Clinical Features	Comment
<i>EPG5</i>	<a href="#">EPG5-related disorder</a> (encompasses classic Vici syndrome)	AR	<ul style="list-style-type: none"> <li>• <i>EPG5</i>-related disorder represents a continuum of variable severity</li> <li>• Vici syndrome (defined as a neurodevelopmental disorder w/ agenesis of the corpus callosum, cataracts, hypopigmentation, cardiomyopathy, combined immunodeficiency, microcephaly, &amp; failure to gain weight) is at the most severe end of the spectrum.</li> <li>• Milder, attenuated neurodevelopmental phenotypes w/a variable degree of multisystem involvement are increasingly recognized.</li> </ul>	<ul style="list-style-type: none"> <li>• Defects of the corpus callosum &amp; cardiac involvement are not typical for CHS.</li> <li>• Giant intracellular granules will not be seen in <i>EPG5</i>-related disorder.</li> </ul>
<i>LAMTOR2</i>	Immunodeficiency due to defect in MAPBP-interacting protein (OMIM <a href="#">610798</a> )	AR	<ul style="list-style-type: none"> <li>• Immunodeficiency syndrome identified in 4 members of a Mennonite family</li> <li>• Clinical features incl partial albinism, short stature, congenital neutropenia, &amp; lymphoid deficiency.</li> </ul>	<ul style="list-style-type: none"> <li>• Neutrophils show altered azurophilic granule ultrastructure &amp; less than normal microbicidal function of phagosomes, in contrast to the giant granules seen in neutrophils in CHS.</li> <li>• Neurologic dysfunction was not described in affected family members.</li> </ul>
<i>MLPH</i> <i>MYO5A</i> <i>RAB27A</i>	Griscelli syndrome (GS) (OMIM <a href="#">PS214450</a> )	AR	<ul style="list-style-type: none"> <li>• Mild skin hypopigmentation &amp; silvery-gray hair plus severe neurologic involvement in <i>MYO5A</i>-related GS &amp; immunodeficiency &amp; lymphohistiocytosis in <i>RAB27A</i>-related GS.</li> <li>• Hypopigmentation is the only clinical characteristic of <i>MLPH</i>-related GS.</li> </ul>	<ul style="list-style-type: none"> <li>• Platelet-dense bodies are present &amp; platelet function is normal.</li> <li>• Giant granules w/in neutrophils are not present in GS.</li> </ul>
<i>PRF1</i> <i>STX11</i> <i>STXBP2</i> <i>UNC13D</i>	<a href="#">Familial hemophagocytic lymphohistiocytosis (fHLH)</a>	AR	<ul style="list-style-type: none"> <li>• Immune deficiency characterized by overactivation &amp; excessive proliferation of T lymphocytes &amp; macrophages, leading to infiltration &amp; damage of organs incl bone marrow, liver, spleen, &amp; brain</li> <li>• Familial HLH usually presents as an acute illness w/prolonged &amp; high fever, cytopenias, &amp; hepatosplenomegaly.</li> <li>• Persons w/fHLH may also exhibit liver dysfunction &amp; neurologic abnormalities.</li> <li>• Although manifestations of fHLH are usually evident w/in 1st mos or yrs of life &amp; may develop in utero, symptomatic presentation can occur throughout childhood &amp; into adulthood.</li> </ul>	The presentation of HLH in CHS will look the same as in fHLH; however, in CHS, giant intracellular granules w/in the leucocytes will be apparent on peripheral blood smear & bone marrow aspirate.

AR = autosomal recessive; CHS = Chediak-Higashi syndrome; HLH = hemophagocytic lymphohistiocytosis; MOI = mode of inheritance; OCA = oculocutaneous albinism

## Management

No clinical practice guidelines for Chediak-Higashi syndrome (CHS) have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.

## Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with Chediak-Higashi syndrome (CHS), the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

**Table 4.** Chediak-Higashi Syndrome: Recommended Evaluations Following Initial Diagnosis

System/Concern	Evaluation	Comment
<b>Ophthalmologic</b>	By pediatric or adult ophthalmologist depending on age	<ul style="list-style-type: none"> <li>Assess for signs of ↓ pigment (see <a href="#">OCA/OA Overview</a>) &amp; refractive errors.</li> <li>Consider OCT to provide baseline retinal fiber thickness.</li> </ul>
<b>Immunologic</b>	Screening for history of frequent or unusual infections	Referral to immunologist &/or hematologist/oncologist for consideration of eval for HSCT
<b>Bleeding disorder</b>	By hematologist	Platelet aggregation studies &/or platelet EM for dense body analysis
<b>Neurologic</b>	By pediatric or adult neurologist depending on age	<ul style="list-style-type: none"> <li>Neurologic exam</li> <li>Specialized testing if abnormalities identified on clinical exam</li> </ul>
<b>Cognitive impairment</b>	<b>Child</b>	Developmental/educational assessment
	<b>Adult</b>	Neuropsychologist
		<ul style="list-style-type: none"> <li>To incl motor, adaptive, cognitive, &amp; speech-language eval</li> <li>Eval for early intervention / need for IEP &amp;/or 504 plan</li> </ul>
<b>Hemophagocytic lymphohistiocytosis</b>	Protocols vary by institution/specialist (See <a href="#">Familial Hemophagocytic Lymphohistiocytosis</a> .)	<ul style="list-style-type: none"> <li>History of unexplained, persistent, or recurrent fever</li> <li>Assessment for hepatosplenomegaly by physical exam &amp; ultrasound imaging</li> <li>Complete blood count <sup>1</sup></li> <li>Ferritin concentration <sup>2</sup></li> <li>Soluble interleukin-2 receptor level <sup>2</sup></li> <li>Consideration of bone marrow biopsy <sup>3</sup></li> <li>Consideration of lumbar puncture</li> <li>Serum triglyceride concentration <sup>4</sup></li> <li>Fibrinogen level <sup>4</sup></li> </ul>
<b>Genetic counseling</b>	By genetics professionals <sup>5</sup>	To inform affected persons & their families re nature, MOI, & implications of CHS to facilitate medical & personal decision making

Table 4. continued from previous page.

System/Concern	Evaluation	Comment
<b>Family support &amp; resources</b>	Assessment of family & social structure to determine the availability of adequate support systems	<ul style="list-style-type: none"> <li>Community or online resources such as <a href="#">Parent to Parent</a></li> <li>Social work involvement for parental support</li> <li>Home nursing referral</li> </ul>

CHS = Chediak-Higashi syndrome; EM = electron microscopy; HSCT = hematopoietic stem cell transplantation; IEP = individualized education plan; MOI = mode of inheritance; OCT = optical coherence tomography

- For evidence of cytopenia involving at least two cell lines
- Elevated serum ferritin and soluble interleukin-2 receptor level are associated with hemophagocytic lymphohistiocytosis (HLH).
- To assess for hemophagocytosis
- Hypertriglyceridemia and hypofibrinogenemia are suggestive of liver dysfunction, which can be associated with HLH.
- Medical geneticist, certified genetic counselor, certified advanced genetic nurse

## Treatment of Manifestations

There is no cure for Chediak-Higashi syndrome.

### Targeted Therapy

*In GeneReviews, a targeted therapy is one that addresses the specific underlying mechanism of disease causation (regardless of whether the therapy is significantly efficacious for one or more manifestation of the genetic condition); would otherwise not be considered without knowledge of the underlying genetic cause of the condition; or could lead to a cure. —ED*

**Hematopoietic stem cell transplantation (HSCT).** The only targeted therapy currently available is HSCT. While HSCT will correct the hematologic and immunologic manifestations of CHS, it does not appear to protect against the development of neurologic manifestations in late adolescence and adulthood.

Preparation for HSCT is often initiated as soon as the diagnosis of CHS is confirmed. HSCT protocols vary by institution.

Best outcomes for HSCT are achieved if initiated prior to the development of hemophagocytic lymphohistiocytosis (HLH); however, if HLH occurs, treatment following the Histiocyte Society HLH-94 protocol is recommended. Once remission of HLH is achieved, HSCT may be performed.

### Supportive Care

Supportive care to improve quality of life, maximize function, and reduce complications is recommended. This can include multidisciplinary care by specialists in relevant fields (see Table 5).

Table 5. Chediak-Higashi Syndrome: Supportive Treatment of Manifestations

Manifestation/Concern	Treatment	Considerations/Other
<b>Skin hypopigmentation</b>	Sunscreen	To prevent sun damage & skin cancer
<b>Ophthalmologic</b>	<ul style="list-style-type: none"> <li>Corrective lenses for refractive errors</li> <li>Sunglasses to protect eyes from UV light</li> </ul>	
<b>Low vision</b>	Low vision rehab & adaptive therapy	<ul style="list-style-type: none"> <li>Children: per educational setting</li> <li>Adults: low vision clinic</li> </ul>

Table 5. continued from previous page.

Manifestation/Concern	Treatment	Considerations/Other
<b>Infections</b>	Prompt & aggressive use of antibiotic & antiviral agents for bacterial & viral illnesses, respectively	Consideration of prophylactic antibiotics in those w/recurrent infections <sup>1, 2</sup>
<b>Infection risk</b>	Inactivated vaccine administration according to typical schedule	<ul style="list-style-type: none"> <li>• Live vaccines not recommended<sup>3</sup></li> <li>• Protection from infectious exposures as much as practical</li> </ul>
	Routine dental cleaning & exam to prevent & monitor for periodontal disease	
<b>Bleeding disorder</b>	Intravenous DDAVP® (0.2-0.4 µg/kg over 15-30 mins) 30 mins prior to invasive procedures	For serious trauma or extensive bleeding, platelet transfusion may be necessary.
<b>Neurologic</b>	Parkinsonism	Trial of L-dopa therapy <sup>4</sup>
<b>Musculoskeletal/ADL</b>	Best provided by team comprising neurologist, physiatrist, PT, & OT	<ul style="list-style-type: none"> <li>• Intensive rehab (or coordinative PT)</li> <li>• Canes/walkers to prevent falls</li> <li>• Home modifications to accommodate motorized chairs as needed</li> <li>• Weighted eating utensils &amp; dressing hooks</li> <li>• Weight control, as obesity can exacerbate difficulties w/ambulation &amp; mobility</li> </ul>
<b>Hematologic &amp; immunologic defects</b>	Guidelines for treatment of HLH same as for familial HLH <sup>5, 6, 7, 8, 9</sup>	<ul style="list-style-type: none"> <li>• HLH-94 protocol is current standard of care &amp; uses combination therapy consisting of etoposide &amp; dexamethasone, w/ continuation phase adding cyclosporine A.</li> <li>• Select persons may also receive intrathecal methotrexate.</li> </ul>
	HSCT <sup>9, 10, 11, 12</sup>	<ul style="list-style-type: none"> <li>• Preparation for HSCT is often initiated as soon as diagnosis is confirmed.</li> <li>• The most favorable outcome is achieved when HSCT is performed prior to development of HLH.</li> <li>• If signs of HLH are present, hemophagocytosis must be brought into clinical remission before HSCT can be performed.<sup>8</sup></li> </ul>



Table 5. continued from previous page.

Manifestation/Concern		Treatment	Considerations/Other
<b>Cognitive/ Educational</b>	<b>Child</b>	By neuropsychologist or developmental pediatrician	Establishment or maintenance of IEP or 504 plan
	<b>Adult</b>	By neuropsychologist	Identification of areas that need support

HLH = hemophagocytic lymphohistiocytosis; HSCT = hematopoietic stem cell transplantation; IEP = individualized education plan; OT = occupational therapist/therapy; PT = physical therapist/therapy

1. McCusker & Warrington [2011]

2. For individuals with compromised immune systems and neutropenia who will be undergoing invasive dental procedures or procedures that cause significant bleeding, prophylaxis should be considered (see [AAPD Reference Manual of Pediatric Dentistry](#)).

3. Principi & Esposito [2014], Sobh & Bonilla [2016]

4. Bhambhani et al [2013], Introne et al [2017]

5. Better HLH control at the time of HSCT leads to better long-term outcome.

6. Recent evaluation of the HLH-2004 protocol did not find statistical evidence for superiority over the HLH-94 regimen; therefore, HLH-94 remains the standard of care [Bergsten et al 2017].

7. The remission induction rate may be as high as 71% when considering all heritable causes of HLH [Filipovich & Chandrakasan 2015].

8. This treatment is also effective at inducing remission in CHS so that HSCT can be performed [Trottestam et al 2009].

9. This is the only treatment that cures the hematologic and immunologic deficits.

10. The conditioning regimen is at the discretion of the treatment center; however, reduced-intensity conditioning regimens have demonstrated improved survival over traditional myeloablative protocols.

11. Although not specific for CHS, in a cohort of 40 individuals with genetic forms of HLH including CHS, the three-year post-HSCT survival was 92% following reduced-intensity conditioning regimens [Marsh et al 2010].

12. The overall five-year survival rate in 35 children with CHS who underwent HSCT was 62% [Eapen et al 2007].

## Surveillance

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations in Table 6 are recommended.

Table 6. Chediak-Higashi Syndrome: Recommended Surveillance

System/Concern	Evaluation	Frequency
<b>Ocular</b>	Ophthalmologic exam	At least annually or as directed by treating ophthalmologist
<b>Skin</b>	Dermatologic exam for routine monitoring of persons w/ hypopigmentation	At least annually
<b>Hematology/Oncology</b>	Post HSCT: monitoring of chimerism <sup>1, 2</sup> & ongoing post-transplant follow up	According to local center recommendations
	If persons have not undergone HSCT, monitor for signs of HLH using combination of: <ul style="list-style-type: none"> <li>Abdominal ultrasound</li> <li>Complete blood count</li> <li>Ferritin concentration</li> <li>Serum triglycerides</li> <li>Fibrinogen level</li> <li>Soluble interleukin-2 receptor level</li> </ul> Consider bone marrow biopsy if findings of above studies suggest HLH.	At least annually, but more frequently if changes in clinical status
<b>Education</b>	Monitor developmental progress & educational needs.	At each visit
<b>Cognitive issues</b>	By primary care physician or psychologist/neuropsychologist	If changes in clinical status

Table 6. continued from previous page.

System/Concern	Evaluation	Frequency
<b>Neurologic</b>	Neurologic exam for signs of peripheral neuropathy, ataxia, signs suggestive of parkinsonism, or other changes from baseline daily functioning & independence	Specialized testing at discretion of treating neurologist based on clinical findings
<b>Musculoskeletal</b>	Physical medicine, OT/PT assessment of mobility, self-help skills	At each visit
<b>Family/Community</b>	Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning).	

HLH = hemophagocytic lymphohistiocytosis; HSCT= hematopoietic stem cell transplantation; OT = occupational therapy; PT = physical therapy

1. Especially in those who undergo HSCT with reduced-intensity conditioning, as the incidence of mixed chimerism in the bone marrow is higher than in those who undergo traditional conditioning.
2. Recent studies suggest that 20%-30% donor chimerism is likely enough to protect against reactivation [Hartz et al 2016].

## Agents/Circumstances to Avoid

Avoid the following:

- Live vaccines given the risk of infection due to immunodeficiency
- All nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) given the risk of exacerbating the bleeding tendency

## Evaluation of Relatives at Risk

**For early diagnosis and treatment.** It is appropriate to evaluate the older and younger sibs of a proband as early as possible. Early diagnosis may provide the opportunity to perform HSCT prior to the development of HLH. Evaluations include:

- Molecular genetic testing if the *LYST* pathogenic variants in the family are known;
- Examination of peripheral blood for the presence of giant granules in white blood cells if the *LYST* pathogenic variants in the family are not known. (Note: Although the giant granules are seen using routine staining techniques, in some individuals with atypical CHS the presence of these giant granules can be somewhat subtle. A hematologist or a clinician experienced in reviewing blood smears for the presence of these giant granules should review the slide.)

**For hematopoietic stem cell donation.** Any relative considering stem cell donation should undergo molecular genetic testing to clarify their genetic status so that informed risk vs benefit discussions for both recipient and donor can be incorporated into transplant donor-option decision making. Whenever possible, related donors who do not have a familial *LYST* pathogenic variant are preferred.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

## Pregnancy Management

Based on the limited number of pregnancies in females with CHS reported in the literature to date, pregnancy, labor, and delivery were uneventful [Price et al 1992, Weisfeld-Adams et al 2013]. The infants were healthy.

Bleeding during delivery and the postpartum period are a concern; thus, prior to delivery developing a plan to deal with possible bleeding is recommended.

## Therapies Under Investigation

A natural history study at the NIH (Study of Chediak-Higashi Syndrome, [NCT00005917](#)) is currently enrolling individuals for longitudinal studies but not offering new therapy.

Search [ClinicalTrials.gov](#) in the US and [EU Clinical Trials Register](#) in Europe for access to information on clinical studies for a wide range of diseases and conditions.

## Genetic Counseling

*Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.*

## Mode of Inheritance

Chediak-Higashi syndrome (CHS) is inherited in an autosomal recessive manner.

## Risk to Family Members

### Parents of a proband

- The parents of an affected individual are usually heterozygous for a *LYST* pathogenic variant.
- If a molecular diagnosis has been established in the proband, molecular genetic testing is recommended for the parents of the proband to confirm that both parents are heterozygous for a *LYST* pathogenic variant and to allow reliable recurrence risk assessment.
- If a pathogenic variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, it is possible that one of the pathogenic variants identified in the proband occurred as a *de novo* event in the proband or as a postzygotic *de novo* event in a mosaic parent [Jónsson et al 2017]. If the proband appears to have homozygous pathogenic variants (i.e., the same two pathogenic variants), additional possibilities to consider include:
  - A single- or multiexon deletion in the proband that was not detected by sequence analysis and that resulted in the artifactual appearance of homozygosity;
  - Uniparental isodisomy for the parental chromosome with the pathogenic variant that resulted in homozygosity for the pathogenic variant in the proband. Two individuals with CHS caused by uniparental disomy of chromosome 1 have been reported [Dufourcq-Lagelouse et al 1999, Manoli et al 2010].
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

### Sibs of a proband

- If both parents are known to be heterozygous for a *LYST* pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
- Sibs who inherit the same biallelic *LYST* pathogenic variants as the proband may present with discrepant phenotypes [Morimoto et al 2023].
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

**Offspring of a proband.** The offspring of an individual with CHS are obligate heterozygotes (carriers) for a *LYST* pathogenic variant.

**Other family members.** Each sib of the proband's parents is at a 50% risk of being a carrier of a *LYST* pathogenic variant.

## Carrier Detection

Carrier testing for at-risk relatives requires prior identification of the *LYST* pathogenic variants in the family.

## Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

### Family planning

- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

**DNA banking.** Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see Huang et al [2022].

## Prenatal Testing and Preimplantation Genetic Testing

Once the *LYST* pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

## Resources

*GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).*

- **MedlinePlus**  
[Chediak-Higashi syndrome](#)
- **Hermansky-Pudlak Syndrome Network, Inc.**  
**Phone:** 800-789-9HPS  
**Fax:** 516-624-0640  
**Email:** [info@hpsnetwork.org](mailto:info@hpsnetwork.org)  
[www.hpsnetwork.org](http://www.hpsnetwork.org)
- **International Patient Organization for Primary Immunodeficiencies (IPOPI)**  
United Kingdom  
**Phone:** +44 01503 250 668

**Fax:** +44 01503 250 668

**Email:** [info@ipopi.org](mailto:info@ipopi.org)

[ipopi.org](http://ipopi.org)

- **National Organization for Albinism and Hypopigmentation (NOAH)**

**Phone:** 800-473-2310 (US and Canada); 603-887-2310

**Fax:** 603-887-6049

**Email:** [info@albinism.org](mailto:info@albinism.org)

[www.albinism.org](http://www.albinism.org)

- **European Society for Immunodeficiencies (ESID) Registry**

**Email:** [esid-registry@uniklinik-freiburg.de](mailto:esid-registry@uniklinik-freiburg.de)

[ESID Registry](http://ESID Registry)

## Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

**Table A.** Chediak-Higashi Syndrome: Genes and Databases

Gene	Chromosome Locus	Protein	Locus-Specific Databases	HGMD	ClinVar
<i>LYST</i>	1q42.3	Lysosomal-traffic regulator	LYST database LYSTbase: Mutation registry for Chediak-Higashi syndrome (previously known as CHS1base) Albinism Database Mutations of the Chediak-Higashi Syndrome gene - LYST	LYST	LYST

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

**Table B.** OMIM Entries for Chediak-Higashi Syndrome ([View All in OMIM](#))

214500	CHEDIAK-HIGASHI SYNDROME; CHS
606897	LYSOSOMAL TRAFFICKING REGULATOR; LYST

## Molecular Pathogenesis

*LYST* encodes the cytoplasmic protein lysosomal-traffic regulator (LYST), also called CHS1. It has been hypothesized that LYST has a role in the regulation of membrane fusion events and lysosomal size [Tanabe et al 2000, Tchernev et al 2002, Möhlig et al 2007, Morimoto et al 2007]. Studies in *Drosophila* have suggested that LYST plays a role in regulating lysosome-related organelle (LRO) formation and in facilitating centrosome maturation and positioning [Lattao et al 2021]. Another study suggested LYST involvement in autophagosome lysosome reformation facilitates fission of autolysosome tubules for lysosomal homeostasis [Serra-Vinardell et al 2023]. However, the precise biologic role of LYST remains unknown.

**Mechanism of disease causation.** Loss of function



**Variants of uncertain significance (VUS).** As the use of broader genomic sequencing increases, identification of VUS is also rising. For individuals identified to have VUS in *LYST*, it is important to correlate the genetic findings with the clinical features following a comprehensive evaluation, specifically taking into consideration the finding of giant granules within leukocytes on the peripheral blood smear (see Suggestive Findings). If a blood smear is unavailable, light microscopy of the hair showing the characteristic pigment clumping throughout the hair shaft may aid in interpretation of VUS.

## Chapter Notes

### Author Notes

Dr Toro is a movement disorder neurologist who works with the National Institutes of Health Undiagnosed Diseases Program.

Dr Morimoto is a scientist who performs translational research in the National Institutes of Health Undiagnosed Diseases Program.

Dr Malicdan is a neurologist and a scientist whose main interest is the study of rare diseases. She performs basic and translational research on rare diseases in the National Institutes of Health Undiagnosed Diseases Program.

Dr Adams is a pediatrician, medical geneticist, and biochemical geneticist who performs clinical and basic research on rare diseases at the National Institutes of Health.

Dr Introne ([wintrone@nih.gov](mailto:wintrone@nih.gov)) is a pediatrician and medical and biochemical geneticist who performs clinical research on rare diseases at the National Institutes of Health. Dr Introne is actively involved in clinical research regarding Chediak-Higashi syndrome and [Hermansky-Pudlak syndrome](#). She would be happy to communicate with persons who have questions regarding the diagnosis of these disorders or other considerations.

### Acknowledgments

The authors would like to gratefully acknowledge the patients with Chediak-Higashi syndrome and their families for contributing to our understanding of CHS over the years. Special thanks to the Chediak-Higashi Syndrome Association and the Hermansky-Pudlak Syndrome Network for their long-standing dedication to research and patient advocacy.

The authors would like to respectfully acknowledge the authors of the Familial Hemophagocytic Lymphohistiocytosis *GeneReview* for allowing us to link to their *GeneReview* and providing expert information on the clinical presentation, diagnosis, and management of HLH.

This work was supported by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.

### Author History

David R Adams, MD, PhD (2009-present)

Gretchen A Golas, RN, MS, CRNP; National Human Genome Research Institute (2009-2018)

Wendy J Introne, MD (2009-present)

May Christine Malicdan, MD, PhD (2018-present)

Marie Morimoto, PhD (2023-present)

Elena-Raluca Nicoli, PharmR, PhD; National Human Genome Research Institute (2018-2023)

Camilo Toro, MD (2018-present)

Wendy Westbroek, PhD; National Human Genome Research Institute (2009-2018)

## Revision History

- 21 December 2023 (bp) Comprehensive update posted live
- 5 July 2018 (ma) Comprehensive update posted live
- 15 January 2015 (me) Comprehensive update posted live
- 16 February 2012 (me) Comprehensive update posted live
- 3 March 2009 (me) Review posted live
- 2 October 2008 (wji) Original submission

Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the *GeneReview* "Chediak-Higashi Syndrome" is in the public domain in the United States of America.

## References

### Literature Cited

- Bailleul-Forestier I, Monod-Broca J, Benkerrou M, Mora F, Picard B. Generalized periodontitis associated with Chediak-Higashi syndrome. *J Periodontol*. 2008;79:1263–70. PubMed PMID: 18597610.
- Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, Ishii E, Janka G, Ladisch S, Lehmborg K, McClain KL, Minkov M, Montgomery S, Nanduri V, Rosso D, Henter JI. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. *Blood*. 2017;130:2728–38. PubMed PMID: 28935695.
- Bhambhani V, Introne WJ, Lungu C, Cullinane A, Toro C. Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism. *Mov Disord*. 2013;28:127–9. PubMed PMID: 23436631.
- Certain S, Barrat F, Pastural E, Le Deist F, Goyo-Rivas J, Jabado N, Benkerrou M, Seger R, Vilmer E, Beullier G, Schwarz K, Fischer A, de Saint Basile G. Protein truncation test of *LYST* reveals heterogeneous mutations in patients with Chediak-Higashi syndrome. *Blood*. 2000;95:979–83. PubMed PMID: 10648412.
- de Arruda JAA, Sousa-Neto SS, Abreu LG, Schuch LF, Souza VG, Alves TVL, Martins-Andrade B, Shetty SS, Monteiro JLGC, Mendonça EF, Mesquita RA, Callou G. Oral manifestations of Chediak-Higashi syndrome: A systematic review. *Dis Mon*. 2023;69:101356. PubMed PMID: 35414415.
- Desai N, Weisfeld-Adams JD, Brodie SE, Cho C, Curcio CA, Lublin F, Rucker JC. Optic neuropathy in late-onset neurodegenerative Chédiak-Higashi syndrome. *Br J Ophthalmol*. 2016;100:704–7. PubMed PMID: 26307451.
- Dufourcq-Lagelouse R, Lambert N, Duval M, Viot G, Vilmer E, Fischer A, Prieur M, de Saint Basile G. Chediak-Higashi syndrome associated with maternal uniparental isodisomy of chromosome 1. *Eur J Hum Genet*. 1999;7:633–7. PubMed PMID: 10482950.
- Eapen M, DeLaat CA, Baker KS, Cairo MS, Cowan MJ, Kurtzberg J, Steward CG, Veys PA, Filipovich AH. Hematopoietic cell transplantation for Chediak-Higashi syndrome. *Bone Marrow Transplantation*. 2007;39:411–5. PubMed PMID: 17293882.
- Filipovich AH, Chandrakasan S. Pathogenesis of hemophagocytic lymphohistiocytosis. *Hematol Oncol Clin North Am*. 2015;29:895–902. PubMed PMID: 26461149.
- Fusaro M, Rosain J, Grandin V, Lambert N, Hanein S, Fourrage C, Renaud N, Gil M, Chevalier S, Chahla WA, Bader-Meunier B, Barlogis V, Blanche S, Boutboul D, Castelle M, Comont T, Diana JS, Fieschi C, Galicier L, Hermine O, Lefèvre-Utile A, Malphettes M, Merlin E, Oksenhendler E, Pasquet M, Suarez F, André I, Béziat V, De Saint Basile G, De Villartay JP, Kracker S, Lagresle-Peyrou C, Latour S, Rieux-Laucat F, Mahlaoui N, Bole C, Nitschke P, Hulier-Ammar E, Fischer A, Moshous D, Neven B, Alcais A, Vogt G, Bustamante J, Picard C. Improving the diagnostic efficiency of primary immunodeficiencies with targeted next-generation sequencing. *J Allergy Clin Immunol*. 2021;147:734–37. PubMed PMID: 32531373.

- Gil-Krzewska A, Wood SM, Murakami Y, Nguyen V, Chiang SCC, Cullinane AR, Peruzzi G, Gahl WA, Coligan JE, Introne WJ, Bryceson YT, Krzewski K. Chediak-Higashi syndrome: lysosomal trafficking regulator domains regulate exocytosis of lytic granules but not cytokine secretion by natural killer cells. *J Allergy Clin Immunol*. 2016;137:1165–77. PubMed PMID: 26478006.
- Hartz B, Marsh R, Rao K, Henter JI, Jordan M, Filipovich L, Bader P, Beier R, Burkhardt B, Meisel R, Schulz A, Winkler B, Albert MH, Greil J, Karasu G, Woessmann W, Corbacioglu S, Gruhn B, Holter W, Kühl JS, Lang P, Seidel MG, Veys P, Löfstedt A, Ammann S, Ehl S, Janka G, Müller I, Lehmborg K. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. *Blood*. 2016;127:3281–90. PubMed PMID: 27099148.
- Huang SJ, Amendola LM, Sternen DL. Variation among DNA banking consent forms: points for clinicians to bank on. *J Community Genet*. 2022;13:389–97. PubMed PMID: 35834113.
- Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. *Mol Genet Metab*. 1999;68:283–303. PubMed PMID: 10527680.
- Introne WJ, Westbroek W, Groden CA, Bhambhani V, Golas GA, Baker EH, Lehky TJ, Snow J, Ziegler SG, Malicdan MC, Adams DR, Horward HM, Hess RA, Huizing M, Gahl WA, Toro C. Neurologic involvement in patients with atypical Chediak-Higashi disease. *Neurology*. 2017;88:e57–e65. PubMed PMID: 28193763.
- Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmborg K, Langler A, Gross-Wieltsch U, Bay A, Kaya Z, Bryceson YT, Koscielniak E, Badawy S, Davies G, Hufnagel M, Schmitt-Graeff A, Aichele P, Zur Stadt U, Schwarz K, Ehl S. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. *Blood*. 2011;118:4620–9. PubMed PMID: 21878672.
- Jónsson H, Sulem P, Kehr B, Kristmundsdóttir S, Zink F, Hjartarson E, Hardarson MT, Hjorleifsson KE, Eggertsson HP, Gudjonsson SA, Ward LD, Arnadóttir GA, Helgason EA, Helgason H, Gylfason A, Jonasdóttir A, Jonasdóttir A, Rafnar T, Frigge M, Stacey SN, Th Magnusson O, Thorsteinsdóttir U, Masson G, Kong A, Halldorsson BV, Helgason A, Gudbjartsson DF, Stefansson K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. *Nature*. 2017;549:519–22. PubMed PMID: 28959963.
- Karim MA, Suzuki K, Fukai K, Oh J, Nagle DL, Moore KJ, Barbosa E, Falik-Borenstein T, Filipovich A, Ishida Y, Kivrikko S, Klein C, Kreuz F, Levin A, Miyajima H, Rigueiro J, Russo C, Uyama E, Vierimaa O, Spritz RA. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. *Am J Med Genet*. 2002;108:16–22. PubMed PMID: 11857544.
- Koh K, Tsuchiya M, Ishiura H, Shimazaki H, Nakamura T, Hara H, Suzuyama K, Takahashi M, Tsuji S, Takiyama Y; Japan Spastic Paraplegia Research Consortium. Chédiak-Higashi syndrome presenting as a hereditary spastic paraplegia. *J Hum Genet*. 2022;67:119–21. PubMed PMID: 34483340.
- Kuptanon C, Morimoto M, Nicoli ER, Stephen J, Yarnell DS, Dorward H, Owen W, Parikh S, Ozbek NY, Malbora B, Ciccone C, Gunay-Aygun M, Gahl WA, Introne WJ, Malicdan MCV. cDNA sequencing increases the molecular diagnostic yield in Chediak-Higashi syndrome. *Front Genet*. 2023;14:1072784. PubMed PMID: 36968585.
- Lattao R, Rangone H, Llamazares S, Glover DM. Mauve/LYST limits fusion of lysosome-related organelles and promotes centrosomal recruitment of microtubule nucleating proteins. *Dev Cell*. 2021;56:1000–1013.e6. PubMed PMID: 33725482.
- Lehky TJ, Groden C, Lear B, Toro C, Introne WJ. Peripheral nervous system manifestations of Chediak-Higashi disease. *Muscle Nerve*. 2017;55:359–65. PubMed PMID: 27429304.
- Lozano ML, Rivera J, Sánchez-Guio I, Vicente V. Towards the targeted management of Chediak-Higashi syndrome. *Orphanet J Rare Dis*. 2014;9:132. PubMed PMID: 25129365.
- Manoli I, Golas G, Westbroek W, Vilboux T, Markello TC, Introne W, Maynard D, Pederson B, Tsilou E, Jordan MB, Hart PS, White JG, Gahl WA, Huizing M. Chediak-Higashi syndrome with early developmental delay

- resulting from paternal heterodisomy of chromosome 1. *Am J Med Genet A*. 2010;152A:1474–83. PubMed PMID: 20503323.
- Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Blessing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. *Blood*. 2010;116:5824–31. PubMed PMID: 20855862.
- McCusker C, Warrington R. Primary immunodeficiency. *Allergy Asthma Clin Immunol*. 2011;7:S11. PubMed PMID: 22165913.
- Möhlig H, Mathieu S, Thon L, Frederiksen MC, Ward DM, Kaplan J, Schütze S, Kabelitz D, Adam D. The WD repeat protein FAN regulates lysosome size independent from abnormal downregulation/membrane recruitment of protein kinase C. *Exp Cell Res*. 2007;313:2703–18. PubMed PMID: 17512928.
- Morimoto M, Nicoli ER, Kuptanon C, Roney JC, Serra-Vinardell J, Sharma P, Adams DR, Gallin JI, Holland SM, Rosenzweig SD, Barbot J, Ciccone C, Huizing M, Toro C, Gahl WA, Introne WJ, Malicdan MCV. Spectrum of *LYST* mutations in Chediak-Higashi syndrome: a report of novel variants and a comprehensive review of the literature. *J Med Genet*. 2023. Epub ahead of print. PubMed PMID: 37788905.
- Morimoto M, Tanabe F, Kasai H, Ito M. Effect of a thiol proteinase inhibitor, E-64-d, on susceptibility to infection with *Staphylococcus aureus* in Chediak-Higashi syndrome (beige) mice. *Int Immunopharmacol*. 2007;7:973–80. PubMed PMID: 17499200.
- Price FV, Legro RS, Watt-Morse M, Kaplan SS. Chediak-Higashi syndrome in pregnancy. *Obstet Gynecol*. 1992;79:804–6. PubMed PMID: 1565370.
- Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. *Vaccine*. 2014;32:3725–31. PubMed PMID: 24837766.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405–24. PubMed PMID: 25741868.
- Sánchez-Guiu I, Antón AI, García-Barberá N, Navarro-Fernández J, Martínez C, Fuster JL, Couselo JM, Ortuño FJ, Vicente V, Rivera J, Lozano ML. Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. *Eur J Haematol*. 2014;92:49–58. PubMed PMID: 24112114.
- Serra-Vinardell J, Sandler MB, De Pace R, Manzella-Lapeira J, Cougnoux A, Keyvanfar K, Introne WJ, Brzostowski JA, Ward ME, Gahl WA, Sharma P, Malicdan MCV. *LYST* deficiency impairs autophagic lysosome reformation in neurons and alters lysosome number and size. *Cell Mol Life Sci*. 2023;80:53. PubMed PMID: 36707427.
- Sharma P, Nicoli ER, Serra-Vinardell J, Morimoto M, Toro C, Malicdan MCV, Introne WJ. Chediak-Higashi syndrome: a review of the past, present, and future. *Drug Discov Today Dis Models*. 2020;31:31-6. PubMed PMID: 33424983.
- Shimazaki H, Honda J, Naoi T, Namekawa M, Nakano I, Yazaki M, Nakamura K, Yoshida K, Ikeda S, Ishiura H, Fukuda Y, Takahashi Y, Goto J, Tsuji S, Takiyama Y. Autosomal-recessive complicated spastic paraplegia with a novel lysosomal trafficking regulator gene mutation. *J Neurol Neurosurg Psychiatry*. 2014;85:1024–8. PubMed PMID: 24521565.
- Shirazi TN, Snow J, Ham L, Raglan GB, Wiggs EA, Summers AC, Toro C, Introne WJ. The neuropsychological phenotype of Chediak-Higashi disease. *Orphanet J Rare Dis*. 2019;14:101. PubMed PMID: 31060595.

- Smith VV, Anderson G, Malone M, Sebire NJ. Light microscopic examination of scalp hair samples as an aid in the diagnosis of paediatric disorders: retrospective review of more than 300 cases from a single centre. *J Clin Pathol*. 2005;58:1294–8. PubMed PMID: 16311350.
- Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. *J Allergy Clin Immunol Pract*. 2016;4:1066–75. PubMed PMID: 27836056.
- Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. *Hum Genet*. 2020;139:1197–207. PubMed PMID: 32596782.
- Talbert ML, Malicdan MCV, Introne WJ. Chediak-Higashi syndrome. *Curr Opin Hematol*. 2023;30:144–51. PubMed PMID: 37254856.
- Tanabe F, Cui SH, Ito M. Abnormal down-regulation of PKC is responsible for giant granule formation in fibroblasts from CHS (beige) mice--a thiol proteinase inhibitor, E-64-d, prevents giant granule formation in beige fibroblasts. *J Leukoc Biol*. 2000;67:749–55. PubMed PMID: 10811017.
- Tchernev VT, Mansfield TA, Giot L, Kumar AM, Nandabalan K, Li Y, Mishra VS, Detter JC, Rothberg JM, Wallace MR, Southwick FS, Kingsmore SF. The Chediak-Higashi protein interacts with SNARE complex and signal transduction proteins. *Mol Med*. 2002;8:56–64. PubMed PMID: 11984006.
- Thumbigere Math V, Rebouças P, Giovani PA, Puppini-Rontani RM, Casarin R, Martins L, Wang L, Krzewski K, Introne WJ, Somerman MJ, Nociti FH Jr, Kantovitz KR. Periodontitis in Chédiak-Higashi syndrome: an altered immunoinflammatory response. *JDR Clin Trans Res*. 2018;3:35–46. PubMed PMID: 29276776.
- Trottestam H, Beutel K, Meeths M, Carlsen N, Heilmann C, Pasić S, Webb D, Hasle H, Henter JI. Treatment of the X-linked lymphoproliferative, Griscelli and Chediak-Higashi syndromes by HLH directed therapy. *Pediatr Blood Cancer*. 2009;52:268–72. PubMed PMID: 18937330.
- Weisfeld-Adams JD, Mehta L, Rucker JC, Dembitzer FR, Szporn A, Lublin FD, Introne WJ, Bhambhani V, Chicka MC, Cho C. Atypical Chediak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease. *Orphanet J Rare Dis*. 2013;8:46. PubMed PMID: 23521865.
- Westbroek W, Adams D, Huizing M, Koshoffer A, Dorward H, Tinloy B, Parkes J, Helip-Wooley A, Kleta R, Tsilou E, Duvernay P, Digre KB, Creel DJ, White JG, Boissy RE, Gahl WA. The severity of cellular defects in Chediak Higashi syndrome correlate with the molecular genotype and clinical phenotype. *J Invest Dermatol*. 2007;127:2674–7. PubMed PMID: 17554367.
- Yarnell DS, Roney JC, Teixeira C, Freitas MI, Cipriano A, Leuschner P, Krzewski K, Stephen J, Dorward H, Gahl WA, Gochuico BR, Toro C, Malicdan MC, Introne WJ. Diagnosis of Chediak Higashi disease in a 67-year old woman. *Am J Med Genet A*. 2020;182:3007–13. PubMed PMID: 32990340.
- Zarzour W, Kleta R, Frangoul H, Suwannarat P, Jeong A, Kim SY, Wayne AS, Gunay-Aygun M, White J, Filipovich AH, Gahl WA. Two novel CHS1 (LYST) mutations: clinical correlations in an infant with Chediak-Higashi syndrome. *Mol Genet Metab*. 2005;85:125–32. PubMed PMID: 15896657.

## License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993–2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).



For questions regarding permissions or whether a specified use is allowed, contact: [admasst@uw.edu](mailto:admasst@uw.edu).